Biomaterials for corneal endothelial cell culture and tissue engineering

Mohit Parekh1,2, Vito Romano3,4,5, Kareem Hassanin3, Valeria Testa6,7, Rintra Wongvisavavit1,8, Stefano Ferrari2, Atikah Haneef5, Colin Willoughby9, Diego Ponzin2, Vishal Jhanji10, Namrata Sharma11, Julie Daniels1, Stephen B Kaye3, Sajjad Ahmad1,12 and Hannah J Levis5

Abstract

The corneal endothelium is the posterior monolayer of cells that are responsible for maintaining overall transparency of the avascular corneal tissue via pump function. These cells are non-regenerative in vivo and therefore, approximately 40% of corneal transplants undertaken worldwide are a result of damage or dysfunction of endothelial cells. The number of available corneal donor tissues is limited worldwide, hence, cultivation of human corneal endothelial cells (hCECs) in vitro has been attempted in order to produce tissue engineered corneal endothelial grafts. Researchers have attempted to recreate the current gold standard treatment of replacing the endothelial layer with accompanying Descemet’s membrane or a small portion of stroma as support with tissue engineering strategies using various substrates of both biologically derived and synthetic origin. Here we review the potential biomaterials that are currently in development to support the transplantation of a cultured monolayer of hCECs.

Keywords

Cornea, tissue engineering, biomaterials, cell culture, endothelial cells

Introduction

Corneal endothelial dysfunction

The cornea is a transparent avascular tissue forming the anterior part of the eye.1 It plays a critical role in transmitting and focusing incoming light onto the retina (Figure 1(a)).2 It consists of five layers with the corneal endothelium (CE) being the posterior monolayer (Figure 1(b)).3 Viability of the CE is crucial for maintaining corneal transparency4 which is preserved through dynamic regulation of corneal hydration between a “leaky” barrier and active ionic pumps on the corneal endothelial cells (CECs).5 The viability using trypan blue staining determine the suitability of the graft for transplantation (Figure 1(c)). However, hexagonality using...
alizarin red stain (Figure 1(d)) along with certain biomarkers such as ZO-1 (Figure 1(e)), Tag-1A3 (Figure 1(f)) and Tag-2A12 (Figure 1(g)) are some of the parameters that are used for characterization of CECs. Damage to these cells may result in loss of transportation of ions and solutes leading to corneal oedema.6,7 As the CECs do not possess regenerative capability in vivo, their health needs to be retained throughout life to prevent the development of corneal oedema.8 Endothelial dysfunction is the most common indication for corneal transplantation.9 The main causes of endothelial dysfunction are the corneal dystrophies, which are usually bilateral, symmetric, slowly progressive, and not related to environmental or systemic factors.10 The most commonly observed dystrophy is Fuchs’ endothelial corneal dystrophy (FECD) accounting for approximately 39% of the global corneal transplants undertaken.9 Degeneration of the CE is heritable and mutations in seven genes (AGBL1, COL8A2, LOXHD1, SLC4A11, TCF4, ZEB1, DMPK) have shown to be causal or highly associated with FECD.11,12 In terms of acquired causes, pseudophakic bullous keratopathy is considered to be the predominant cause of endothelial failure.

Current treatment strategy

The gold standard treatment for corneal endothelial disease or dysfunction is corneal transplant (Figure 2) where a diseased corneal endothelium is replaced with a healthy donor corneal endothelium (Figure 2(a)–(d)). When the technique was first introduced, full thickness corneal replacement was a standard practice, known as a penetrating keratoplasty (PK) (Figure 2(e)), and is still used along with anterior lamellar keratoplasty (Figure 2(f)) in cases where stromal scarring is present. In cases where the stroma is unaffected and only the endothelial layer is defective than a lamellar technique can be used. These include the Descemet’s stripping automated endothelial keratoplasty (DSAEK) (Figure 2(g)) and more recently the Descemet’s membrane endothelial keratoplasty (DMEK; Figure 2(h)). Both techniques involve the transplantation into the anterior chamber of a healthy monolayer of hCECs from a cadaveric donor along with either just the Descemet’s membrane (DM) or the DM and a portion of stroma (usually <100 µm). This layer is then attached to the posterior surface of the cornea (recipient DM and endothelial layer removed) with an air tamponade. The DMEK procedure is favored by some surgeons because of the faster recovery of visual acuity but the drawback is that rebubbling rates, due to graft detachment, can be higher in DMEK than in DSAEK.13–15

New approaches to corneal endothelial replacement

A key issue with corneal transplantation is the limited availability of suitable donor tissue; the number of patients that require treatment is much greater than the number of donors available.9 This is especially true in developing countries.
where cadaveric donation is limited due to absence of eye bank facilities, religious and cultural factors, and lack of knowledge about donation.\textsuperscript{16,17} Even when donation is high in a particular region, approximately one third of harvested donor tissues are not suitable for transplant due to low endothelial cell count or presence of infectious agents upon screening.\textsuperscript{9} Another limitation of the cadaveric donor transplantation is the long-term risk of allogenic graft rejection and failure.\textsuperscript{18} Transplant failure is often due to loss of hCECs from the donor layer. It has been reported that 30\% of hCECs are lost within the first 6 months of transplantation.\textsuperscript{19} There is an opportunity to develop biomaterials that not only serve as a scaffold for hCEC transplantation but also may enhance cell function to increase the long-term success of transplanted grafts or even improve the in vitro expansion success of hCECs. Biomaterials for tissue engineering can be characterized in a number of ways. Here we classify them based on their origin into biologically derived, synthetic, and semi-synthetic.

**Isolation and expansion of hCECs**

Cell-based therapies for the cornea are characterized by the isolation of single cells from a cadaveric donor cornea, usually using enzymatic digestion, to allow expansion of their number in vitro. A commonly used method optimized by Peh et al.\textsuperscript{20} involves removing the DM and placing this into collagenase to lift the cells from the DM, followed by Tryple Express to break up the cell clumps to leave a single cell suspension. The single cells are then collected and plated onto fibronectin collagen and albumin (FNC) coating mix coated plates in medium that enhances attachment. This medium is then changed after cells have attached to one that promotes expansion before being placed back into the original medium to maintain their phenotype after about 2 weeks in culture. Cells expand in number over time and then can be harvested for use to treat multiple patients rather than the usual 1:1 ratio that is seen for most cadaveric corneal donations.

**Injected cell therapy**

One recent development in the attempt to produce a new therapy for CEC replacement is the CEC-injection approach pioneered by Kinoshita and his colleagues.\textsuperscript{21–24} In this approach the cultivated CECs are directly injected into the anterior chamber of the recipient. The patient must then remain face down for 2–3 h to allow the cells to attach to the recipient posterior cornea. A very recent study was published reporting a 5 year follow up of 11 patients who were treated with a CEC injection in a first-in-human study.\textsuperscript{25} The results were promising, showing that the best corrected visual acuity (BCVA) was significantly improved in 10 treated eyes and no adverse reactions to the hCEC injection were observed. Importantly, the authors claim that from one donor cornea, at least 300 eyes can be treated using this therapy. It is worth noting, however, that the DM of the patients was not intentionally removed, only abnormal materials on the host DM were mechanically removed in an 8 mm diameter central area. This is because it has
been found that the injected CECs do not form a functional monolayer and are unable to improve corneal transparency or reduce corneal thickness in a rabbit model of corneal damage when directly injected onto the bare stroma after DM removal.\textsuperscript{26} It is likely that they undergo endothelial mesenchymal transition (EMT) and do not form a complete, functional barrier. The FECD cases in the study (n=7) all show the remaining presence of corneal guttue even after 5 years. One limitation of this therapy, therefore, is that it would not be suitable for patients that have extensive guttue in the central field of vision as it has been shown that corneal guttue, even without oedema, cause the quality of vision to deteriorate due to intraocular forward scatter resulting in visual disturbances.\textsuperscript{27}

Harvesting and expanding CECs to gain sufficient numbers for cell or tissue engineering therapies is not easy and can be very donor dependent; younger donors can be more easily expanded in vitro although methods have been devised to encourage the expansion of older donors using techniques such as forced adherence.\textsuperscript{28} Consequently, numerous investigations have been undertaken to optimize the expansion procedure, many using different biomaterials as culture substrates, summarized in Table 1.

**Biologically derived materials**

Extracellular matrix proteins are particularly important in terms of attachment and expansion of hCECs in culture as well as a potential coating on materials for transplantation. The most common and extensively studied ECM proteins are collagens, fibronectin and laminins. In order to assess the effects of these proteins on the hCECs, tissue culture plates are coated with ECM proteins, either one or a combination of proteins (i.e. FNC Coating Mix\textsuperscript{29}—fibronectin, collagen, and albumin) and then compared to uncoated plates. One study that looked at a number of factors that may affect the success of isolation and culture of CECs included a study on ECM proteins.\textsuperscript{30} They concluded that FNC coating was the best surface with 56% of cultures grown on these plates being scored a success compared to only 23% from fibronectin, and 8% grown on collagen IV. The results of another study suggested that fibronectin overall performed the best. All proteins (collagen I, collagen IV, fibronectin, and FNC coating) except laminin increased hCEC adhesion compared to uncoated control.\textsuperscript{31} In fact, laminin-5 has shown mixed results; another study showed that there was a statistically significant increase in cellular proliferation and cellular adhesion on the laminin-5 coated surface compared to fibronectin, with similar adhesion to collagen IV.\textsuperscript{31} The conflicting results seen are perhaps due to different techniques and growth factors used in these studies but could also be related to the isoform of laminin used. A more recent study compared the effect on hCECs of coating with laminin-511, -521, and -211.\textsuperscript{32} They found that the -511 and -521 isoforms did increase the number of adherent and proliferating hCECs compared to control uncoated plates, whereas -211 has no effect. The 511 and 521 isoforms also maintained the cell density and functional phenotype of the CECs after over 100 days in culture. These two isoforms were also found to be expressed in the DM. Laminin-511 has also been shown to promote rapid adhesion, tight junction formation and expression of Na\textsuperscript{+}/K\textsuperscript{+}-ATPase in CECs injected directly into the anterior chamber of a rabbit model of endothelial disease.\textsuperscript{33} Laminin-511 was injected into the anterior chamber before injections of CECs and was found to settle to form a coating on the posterior surface of the DM. The corneal clarity in the laminin group was restored 7 days before the control group. Another study reported that when hCECs were cultured on ECM derived from human corneal endothelial cell line HCEC-12 (Figure 3), cell doubling time was significantly less in the whole ECM group compared to FNC control. This is because the secreted ECM retains the physiological environment, that is, proteins and growth factors that are required for the growth of hCECs.\textsuperscript{34} Although there are conflicting results related to the best ECM protein to coat for cell culture and expansion it is clear that an ECM protein is better than no coating. The choice will ultimately need to be optimized by the end user as it may be dependent on the donor material, and if used for coating a biomaterial for transplant, the characteristics of that particular material.

**Synthetic materials**

The key to a useful biomaterial for CEC expansion is to provide a stable, easily usable polymer, which may have initial cell adhesion properties as well as allowing detachment of a cohesive monolayer when required. With respect to this, the most successful synthetic polymer to date is the temperature-responsive polymer poly(N-isopropylacrylamide) (PIPAAm), which is already being used clinically for corneal epithelial cell expansion.\textsuperscript{35} The regulation of the temperature in a controlled manner allows both the initial adhesion (37°C) and the latter detachment (20°C) of the cells from the PIPAAm.\textsuperscript{36–39} As highlighted in a review, a number of studies have shown that PIPAAm supports important structures such as the Na\textsuperscript{+}/K\textsuperscript{+}-ATPase pump and morphology of CECs with the presence of microvilli and cellular interconnections.\textsuperscript{2} Rabbit models have been used to assess cell functionality after culture on PIPAAm.\textsuperscript{37–39} The cell layers were retrieved from the PIPAAm surfaces and transferred to gelatin disc carriers for transplantation into the rabbit anterior chamber. Both, the clarity of the cornea and the corneal thickness returned to normal within 2 weeks and histological examination suggested the hCECs were spread over the DM with tight junction formation between cells. The effect of the temperature change on the bioactivity of hCECs remains to be investigated as does the implications of the degradation of the gelatin disc within the anterior chamber.
Table 1. Summary of the advantages and limitations of each material for the two different applications of hCEC culture and scaffold based tissue engineering for the corneal endothelium.

| hCEC culture | Category                        | Type                                      | Advantages                                                                                                               | Limitations                                                                                      | In vivo model using hCECs |
|--------------|---------------------------------|-------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|--------------------------|
|              | Biologically derived            | Extracellular matrix proteins<sup>29,30</sup> (collagens I, IV,<sup>31</sup> fibronectin, laminin<sup>32,33</sup> FNC coating, whole ECM)<sup>34</sup> | Mimic components of DM, improve adhesion and proliferation, maintain phenotype | No consensus on best one, can be animal derived and not well defined | N/A                      |
|              | Synthetic                        | Temperature responsive polymers (poly(N-isopropylacrylamide) (PIPAAm))<sup>35-39</sup> | Stable, well defined, whole cell sheet recovered | Fragile, requires another biomaterial for transplant, effect of temp. change on cells not known | Rabbit                   |
|              | Semi-synthetic                  | Chemo-mechanical biomimetics (Polydimethylsiloxane based)<sup>10</sup> | Proliferation and phenotype of cells maintained, mimics basement membrane | Not easy to scale up | N/A                      |

| Scaffold based tissue engineering | Category                        | Type                                      | Advantages                                                                                                               | Limitations                                                                                      | In vivo model using hCECs |
|----------------------------------|---------------------------------|-------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|--------------------------|
|                                  | Biologically derived            | Amniotic membrane<sup>41-46</sup> | Inert, non-cytotoxic, low rejection, proven biocompatibility in the eye | Availability from donor bank, reproducibility, lack of mass manufacturing, sub-optimal transparency, variable rate of biodegradability, risk of contamination and transmission of infectious diseases | Rabbits, cats             |
|                                  | Silk Fibroin<sup>47-53</sup>    | Low immunogenicity, good transparency, non-toxic, controlled degradation rate |                                                                                                                         | Low elasticity and mechanical strength, fragile, difficult to handle and manufacture, decreased biocompatibility, and increased hypersensitivity | Rabbit                   |
|                                  | Human anterior lens capsule<sup>54,55</sup> | Capability to maintain intact barrier, good adhesion to bare stroma, bio-mechanical properties similar to DMEK grafts |                                                                                                                         | Sourced from cadaveric donors, reproducibility, lacks mass manufacturing potential | Pigs                      |
|                                  | Decellularized corneas<sup>56-58</sup> | Capability to maintain intact barrier and ionic pump function, retains transparency, ultrastructure, mechanical properties |                                                                                                                         | Can be a lengthy process, dependent of the availability of the tissues, no data on human corneas | Rabbit                   |
|                                  | Fish scales<sup>59-62</sup>     | Cytocompatible, transparency, good availability |                                                                                                                         | Cell proliferation poor, low adherence, irregular topography | In vitro only             |

(Continued)
| Scaffold based tissue engineering | Category | Type | Advantages | Limitations | In vivo model using hCECs |
|----------------------------------|----------|------|------------|-------------|-------------------------|
| | | Plastic compressed collagen | Rapid scalable production, improved mechanical strength, capability to maintain intact barrier | Transparency not optimal, no in vivo studies | Porcine ex vivo |
| | | Gelatin | Low antigenicity, maintains cell binding motifs, inexpensive, widely availability, permeability to water, transparency, elastic modulus, porosity, good cell adherence | Less relative modifiability compared to synthetic polymers, lack of stability as corneal graft, unknown cytocompatibility with hCECs | Monkey, rabbit |
| | | Synthetic | Biocompatibility and biodegradability | Low strength, induces inflammation | Rabbit |
| | | | Good cell adhesion and growth, properties can be controlled for customized manufacturing, good mechanical properties and transparency, can be functionalized with synthetic peptides | No in vivo studies or use with hCECs | Porcine ex vivo, HCEC-12 and porcine cells |
| | | Electrospray/electrosprayed | Transparency, cytocompatibility, bioactive compounds can be incorporated | Limited studies | In vitro only |
| | | 3D bioprinting | CECs survive the process, graft size can be chosen | Other materials still required as base, hCEC cells not confluent after 10 days | Rabbit |
| | | Gelatin methacrylate (GelMA+) | Increased mechanical strength, maintains cell binding motifs, cytocompatible, increased modifiability compared to gelatin | Expensive and lengthy production process, no in vivo studies | In vitro only |
| | | Chitosan and polycaprolactone | Biodegradable, FDA approved, mechanical property, promote cell adhesion and ECM production, functional maintenance of cells | No in vivo studies | In vitro only |
| | | Chitosan and PEG | Tensile strain and stress similar or greater to cornea, good transparency, good cell attachment and proliferation | No in vivo studies | Sheep |
| | Semi-synthetic | Poly(ethylene glycol) | Good cell adherence and growth, properties can be controlled for customized manufacturing, good mechanical properties and transparency, can be functionalized with synthetic peptides | Cytotoxic, low viscosity | In vitro only |
| | | Biocompatibility and biodegradability | Low strength, induces inflammation | Rabbit |
| | | Good cell adhesion and growth, properties can be controlled for customized manufacturing, good mechanical properties and transparency, can be functionalized with synthetic peptides | No in vivo studies or use with hCECs | Porcine ex vivo, HCEC-12 and porcine cells |
| | | Moderate biocompatibility, modifiability of transparency | Low strength, induces inflammation | Rabbit |
| | | Biocompatible, FDA approved for many applications | Expensive, no in vivo studies | In vitro only |
| | | Biocompatible, maintenance of hCEC morphology, fibers can be aligned | No in vivo studies | In vitro only |

Table 1. (Continued)
A study by Palchesko et al.\textsuperscript{40} showed that a bioengineered substrate recapitulating the chemo-mechanical properties of DM improved the in vitro expansion of CECs while maintaining phenotype. It was observed that the bovine CECs cultured on a polydimethylsiloxane surface with elastic modulus of 50 kPa and collagen IV coating achieved 3000-fold expansion. Cells grew in higher-density monolayers with polygonal morphology and ZO-1 localization at cell-cell junctions in contrast to control cells on tissue culture polystyrene that lost these phenotypic markers and showed increased \(\alpha\)-smooth muscle actin expression and fibronectin fibril assembly. The results demonstrate that a biomimetic substrate presenting native basement membrane ECM proteins and mechanical cues may be a key element in optimizing the expansion of CECs for potential therapeutic applications.

**Semi-synthetic materials**

An alternative approach to injected therapy is the use of cells combined with a biomaterial to create tissue engineered grafts for transplantation. This involves isolating and expanding the cells in the same way as for cell injection but then seeding them onto a scaffold to allow them to form a confluent monolayer before transplantation (Figure 4). There have been challenges associated with this approach, most notably being able to provide the specialized environment required for favorable expansion followed by maintenance of an endothelial phenotype as well as production of a robust endothelial tissue which can be handled without difficulty for transplantation.\textsuperscript{2} Steps have been made to combat this, including the use of different types of biomaterials, with the aim of mimicking some of the features of DM as a base or scaffold to cultivate the hCEC monolayer. These approaches have been trialed in in vivo animal models but, so far, not in humans. Here, we compare different types of biomaterials and assess their potential advantages and drawbacks, summarized in table 1.

**Biologically derived materials**

Amniotic membrane. Amniotic membrane (AM), a natural, inert, non-cytotoxic biological material,\textsuperscript{41} has a major advantage as it reduces the chances of potential graft rejection due to its proven biocompatibility in ocular applications (Figure 5). Studies in cats\textsuperscript{42} and rabbits\textsuperscript{43} have also shown positive results in the maintenance of a corneal endothelial layer of appropriate thickness, which is important in allowing cells to refract incoming light. Despite its advantages, the AM has a number of limitations; including availability from a donor bank. Structurally the transparency of the CE is vital for its function,\textsuperscript{44} therefore the semi-opaque nature of the AM is a concern. Only one study has reported the transplantation of cultivated cat CECs using AM, where the AM becomes transparent after 6 months.\textsuperscript{42} The long-term graft survival suggests that its rate of biodegradability is of particular concern.\textsuperscript{45} Ishino et al.\textsuperscript{43} investigated the morphology and structure of hCECs transplanted on denuded AM using vital
staining and scanning and transmission electron microscopy. They found that the ultrastructure and density of these cells was very similar to that of normal CECs ex vivo, thus suggesting that AM is a suitable substrate for maintaining the endothelial phenotype in vitro. The same group transplanted hCECs on denuded AM into an in vivo rabbit model and showed that at day 7 after surgery, the graft presented flat polygonal endothelial cells with uniform size and presence of tight junctions. The corneas retained their thickness and transparency compared with the denuded AM controls for 1 week. Because rabbit CECs have been known to proliferate in vivo, the extent of survival of hCECs transplanted in vivo using DiI labeling was also studied. The results of the DiI labeling showed that the hCECs remained on the denuded AM transplanted onto the corneal button for at least 4 weeks. Even though AM appears to function well as a scaffold for hCECs, it is associated with a risk of contamination and transmission of infectious diseases. Furthermore, there is biological variability between donor tissues, sub-optimal transparency, and unpredictable degradation rates, all of which has limited its use in the context of corneal endothelial tissue engineering.

**Silk fibroin.** Silk fibroin (SF), a natural fibrin derived from silk has low immunogenicity, good transparency, is non-toxic and displays a controlled degradation rate. However, it has low elasticity and so can easily present surface cracks during the production or handling processes. A 5 µm thick transparent membrane of SF was used to culture hCECs. This material can support growth of CECs, thus suggesting that it can be used as a scaffold for tissue engineering and corneal endothelial reconstruction. A silk fibroin-based artificial endothelial graft was transplanted as a DMEK into a rabbit eye. After surgery, the graft restored the corneal transparency and reduced the thickness of the cornea at 6 weeks follow-up. The rabbit CECs exhibited monolayer morphology and showed characteristic markers ZO-1 and Na+/K+-ATPase. Other studies have investigated SF modified with glycerol, β-carotene, or collagen type

---

**Figure 4.** Tissue engineering of the cornea. Cadaveric donor corneas suitable for research are acquired. The hCECs are isolated as per optimized protocols and allowed to expand in number in culture. Once there are sufficient number of cells, they are transferred onto a scaffold which can be biologically derived, synthetic or semi-synthetic. Multiple grafts can then be produced as a confluent monolayer of cells on the biomaterials. These grafts can then be introduced into the anterior chamber of an animal for research purposes with the eventual goal of transplanting into humans. Figure created with BioRender.com.
Figure 5. Biologically derived material. Amniotic membrane is excised from the umbilical cord, processed and preserved on nitrocellulose paper. Amniotic membrane is used for culturing corneal endothelial cells.

I,52 as a potential substrate for CEC regeneration. Previous studies have reported the decreased biocompatibility and increased hypersensitivity of silk-based materials due to presence of sericin.52 To overcome this issue, Song et al.48 created a silk fibroin film modified with glycerol (G/SF), used as plasticizer, and showed that G/SF films have better physical and mechanical properties, and thinner with respect to the SF films. In vitro tests showed promising results compared with the SF film: G/SF can induce an increase in CECs initial adhesion and proliferation rate when compared with the SF film.48 Kim et al.51 enhanced SF film with β-carotene (β-C). β-C, a vitamin A precursor, has been reported to enhance cell proliferation and differentiation. They showed that a proper amount of β-C incorporated with SF based film scaffolds for rabbit CECs can improve cell viability compared to SF film, moreover β-C/SF scaffolds showed more tight cell junctions and uniform cell size, and showed higher mRNA expression of Na⁺/K⁺-ATPase, aquaporin-1, chloride channel protein 3, sodium/bicarbonate co-transporter 1 and voltage-dependent anion channel 2.51 In vitro studies using rabbit CECs (rCECs) were conducted testing silk films surface-coated with collagen type I (Col-I/SF) to increase cell attachment. Morphological and structural characteristics were studied that showed small-sized pores and dense surface regularity values compared to the SF film, with good transparency and hydrophilicity reported. In vitro biological studies showed an increase in attachment and proliferation of cultured rCECs on the Col-I/SF films. No significant changes in the expression of ZO-1 and Na⁺/K⁺-ATPase were described.52 Kim et al.53 used transparent ultrathin film scaffolds fabricated from aloe vera (AV) gel blended with silk fibroin. It was observed that incorporation of a small amount of AV gel increased cell viability and maintained cell function. These scaffolds were transplanted in rabbit eyes and they attached to the stroma without significant inflammatory reactions. Although the SF films show good compatibility with CECs the major drawback of SF is that the films that have been trialed in this area lack the mechanical strength required for surgical use and can be very fragile upon handling.

Human anterior lens capsule. Human lens (Figure 6) is found in the anterior chamber of the eye, which refracts the surrounding light directed by the cornea towards the retina. Opacification of the lens caused due to aggregated protein deposition as a result of age can result into cataracts. The lens is clear and is covered by a smooth, transparent basement membrane called lens capsule, which is elastic and composed of type IV collagen and sulfated glycosaminoglycans. Yoeruek et al.54 evaluated the potential of human anterior lens capsule (HALC) as a scaffold for cultivating and transplanting hCECs. The HALCs were obtained during cataract surgery, enzyme-digested to remove the lens epithelium and finally plated with the epithelial side up. hCECs were grown to confluence and
formed a continuous viable monolayer. Immunohistochemistry showed tight junctions (ZO-1) and pump functions $\text{Na}^+/$$\text{K}^+\text{-ATPase}$ along with expression of connexin-43 and cytokeratin 3 (AE5). HALCs were thus determined to have the capability of maintaining intact barrier and ionic pump functions in vitro. A more recent study looked at HALCs as carriers for cultivated porcine CECs. The cells formed a monolayer of hexagonal, tightly packed cells that expressed ZO-1 and $\text{Na}^+/$$\text{K}^+\text{-ATPase}$. In this study they also analyzed the handling ability of the grafts using a clinically applicable method. They noted that the constructs behaved in a similar way to a DMEK during implantation and unfolding in an artificial anterior chamber model, with good adhesion to a bare stroma. These physical tests are required as cell compatibility is not the only important parameter to consider. The main issue with the use of HALC as a scaffold for tissue engineering is that, being a biological material, it heavily relies on the supply of cadaveric eye donors.

**Decellularized corneas.** Bayyoud et al. evaluated the potential of decellularized bovine corneas as a carrier for cultivating and transplanting hCECs. After chemically decellularizing the bovine corneas and culturing the hCECs, it was found that bovine cells were substantially removed from the stroma and DM. A statistically significant amount of DNA reduction was observed before and after decellularization. hCECs exhibited viable, polygonal, monolayer morphology with

---

**Figure 6.** Human crystalline lens is obtained from cadaveric eye donors. The lens epithelium is enzymatically isolated and the remaining capsule is used for culturing corneal endothelial cells in vitro.
endothelial cell density (ECD) >2300 cells/mm² with expression of cytokeratin 3 (AE5), collagen type VIII, ZO-1, CX-42, NaHCo₃, and Na⁺/K⁺-ATPase. These phenotypical properties of hCECs imply that the hCEC sheets are capable of maintaining an intact barrier and ionic pump function in vitro. Recently, acellular porcine corneas (Figure 7) were co-cultured with limbal epithelial cells and CECs derived from human embryonic stem cells. Corneal endothelial cells presented their specific markers N-cadherin, ZO-1, and Na⁺/K⁺-ATPase. After cultivation, the acellular porcine corneal scaffold was transplanted into a rabbit eye. The results showed that the tissues were well-integrated with host corneas and corneal clarity was increased without adverse effects. A recent publication has detailed the development of a method to rapidly decellularize a porcine cornea using sodium N lauroyl glutamate and supernuclease. This process allowed the removal of xenoantigen DNA within 3 h, while still retaining transparency, ultrastructure and mechanical properties of the corneas. In vivo studies confirmed there was no immune rejection and transparency was maintained. This method has shown potential to increase the appeal of the use of decellularized materials as previously the process had been criticized for being too lengthy.

Fish scales. In 2010, Lin et al. proposed the use of an oxygen- and glucose-permeable collagen scaffold derived from decalcified fish scales (Tilapia; Oreochromis mossambicus) that can be used in corneal regeneration. Until now, preliminary in vitro studies have shown cytocompatibility of corneal epithelial cells on these heterogeneously patterned, biological scaffolds. Its architectural features have been suggested as an important characteristic for corneal epithelial cell migration and growth. Moreover, its transparency and availability, i.e. roughly 200 scales from
one fish, makes it an attractive biocompatible material for generation of corneal epithelial cell grafts. Additional in vivo studies performed on rats and rabbits have demonstrated its potential as a deep anterior lamellar keratoplasty (DALK) alternative or to seal perforated corneas, respectively. However, a recent report suggested that the fish scale derived scaffold in its current form may not be ideal for the development of tissue engineered corneal endothelial constructs. Although hCECs adhered to the surface of the scales, regional differences in cellular proliferation were observed. The morphology of the cells was also inconsistent with some areas appearing nicely cobblestone but others showing more fibroblastic-like phenotypes. Further modification of the substrate, such as surface polishing to remove the irregular topography, overall thinning of the scaffold and coating with ECM proteins such as fibronectin, could drastically improve its geometric and physical characteristics whilst also enhancing cell-matrix interactions. Post-modification fish scale scaffolds do show some promise due to their inherent transparency once de-calcified and good mechanical properties allowing easy folding like DSAEK grafts.

**Plastic compressed collagen.** Levis et al. described the use of a Real Architecture for 3D Tissues (RAFT) biomaterial that is based on the process of plastic compression of collagen type I. RAFT is a simple and rapid method of production, which yields multiple reproducible constructs with limited variability between batches. The process to manufacture RAFT requires collagen and a plunger (Figure 8(a)) to pressure-build the scaffold (Figure 8(b)). Moreover, it was noted that RAFT is a superior biomaterial in terms of...

---

**Figure 8.** Preparation of Real Architecture for 3D Tissues (RAFT) scaffolds: (a) collagen mixture is pressurized using a plunger to form (b) RAFT scaffolds. The transparency is checked using (c) a transparent slide as a control and compared with (d) the RAFT scaffold. RAFT, as observed under light microscope (e) without cells, and (f) with cultured corneal endothelial cells in vitro.
its transparency (Figure 8(c) and (d)), mechanical strength as it is sufficient to withstand the manipulation that would be required for transplantation without the need for any chemical crosslinking that may have deleterious effects on the behavior of cells on the surface or after transplantation. RAFT is shown to be a highly effective, novel carrier for hCECs (Figure 8(e)). Both hCEC lines and primary hCECs retained their morphologic and molecular characteristics for up to 14 days when they were cultured on these scaffolds (Figure 8(f)). This was demonstrated by the successful loading and delivery of a RAFT with hCECs to an ex vivo porcine eye using a clinical insertion device.

**Gelatin.** Gelatin is a potentially useful biomaterial in tissue engineering applications as it is chemically similar to ECM proteins, has low antigenicity, cost effectiveness, abundance, and accessible functional groups that can allow chemical modifications. Kimoto et al. evaluated novel bioengineered CEC sheets based on a gelatin hydrogel that fit to the curvature of the posterior corneal surface. Monkey CECs were seeded on the hydrogels and the cells were examined by immunohistochemistry after transplanting these scaffolds into a monkey model of bullous keratopathy. These sheets showed permeability to water and protein similar to that of atelocollagen and vitreous keratopathy. These sheets showed permeability to water and protein similar to that of atelocollagen and vitreous keratopathy. Monkey CECs expressed tight junction proteins and ion pumps were normal, N-cadherin was also expressed. Transparency and thickness was maintained. It was noted that these spherically curved gelatin hydrogel sheets achieved close adhesion to the posterior corneal surface. Monkey cells expressed tight junction proteins and ion pumps were normal, N-cadherin was also expressed. Transparency and thickness was maintained. It was noted that these spherically curved gelatin hydrogel sheets achieved close adhesion to the posterior corneal surface without wrinkling and may be useful clinically. It is worth noting, however, that hCECs were not used in that study so their compatibility with the material needs to be tested.

Niu et al. prepared a series of transparent gelatin fabricated scaffolds modified with heparin. It was observed that heparin-modified scaffolds displayed a greater capacity to absorb basic fibroblastic growth factor (bFGF) and showed better release kinetics for up to 20 days. It was also noted that the release of bFGF from the scaffolds improved the survival of hCECs and further reduced cellular loss. An in vivo animal study showed that these scaffolds were flexible enough to be folded and implanted in rabbits’ eyes through a small incision in the cornea. The scaffolds adhered to the inner surface of the corneal stroma and gradually integrated with the surrounding tissue. Thus, the results indicate that gelatin based corneal scaffolds modified to absorb and release growth factors and seeded with hCECs could be useful for transplantation purposes.

**Chitosan blends.** Chitosan is a biomimetic polysaccharide derived from chitin, a component of the exoskeleton of crustaceans. It has high biocompatibility and biodegradability, but low strength, therefore, to enhance its suitability for this application it was combined with two other naturally occurring materials. A polymer that consisted of hydroxyethyl chitosan, gelatin, and chondroitin sulfate was created. In terms of cultivation of hCECs on the substrate, results were encouraging with a significant increase in cell proliferation seen by day 4, and both the membrane permeability and cell organization were comparable to the native human cornea. It was then inserted into the anterior chamber of the rabbit models, where after 3 weeks, the cornea retained its clarity and structure. Unfortunately, inflammation was noticed initially at the corneal-iris junction but no information was provided about ECD at 3 weeks, which is important when considering that inflammation can lead to endothelial cell loss (ECL). Whilst these results look promising, this formulation is still in the experimental stage with more work required to ascertain its suitability for human use.

**Synthetic materials**

**Poly-ε-lysine peptide hydrogel.** Kennedy et al. proposed the use of a synthetic peptide hydrogel using poly-ε-lysine (pεK), cross-linked with octanedioic-acid as a potential substrate for CEC expansion, using hCEC lines and primary porcine endothelial cells. A human corneal endothelial cell line (HCEC-12) attached and grew on pεK hydrogels as confluent monolayers after 7 days, while porcine CECs (pCECs) required functionalization of the pεK hydrogel with a synthetic cell binding peptide to adhere. This resulted in enhanced pCEC adhesion and growth, with expression of ZO-1 and $\text{Na}^+/\text{K}^+$-ATPase at 5 weeks, suggesting a functional corneal endothelial layer. The advantage of synthetic biomaterials is that their properties can be tightly controlled to produce a customized material. This particular biomaterial also has a number of free amine sites allowing functionalization of the surface with synthetic peptides if required, which make it even more customizable (Figure 9(a)). The mechanical properties and transparency can also be modified depending on the formulation, percentage crosslinking, and type of crosslinker. The formulation has been optimized to provide high transparency, mechanical properties to allow loading and delivery from a clinical graft delivery device and adhesion, and expansion of primary cells on the surface (Figure 9(b)–(d)) This synthetic peptide shows great potential to be a suitable scaffold to create a tissue engineered corneal endothelial graft.

**Polymethylmethylmethacrylate, poly(lactic-co-glycolic acid), and polycaprolactone.** In the last few years there has been a mounting interest in the fabrication of tissue-engineered scaffolds by a process referred to as electro-spinning. Kruse et al. tested the cultivation of human CECs on electro-spun scaffolds, obtained from three different synthetic polymers: poly(methyl-methacrylate) (PMMA), poly(lactic-co-glycolic acid) (PLGA), and polycaprolactone (PCL). Cultivation was examined after 3–7 days of
incubation: PMMA showed significant cytotoxicity, while PLGA and PCL electro-spun scaffolds resulted in equal biocompatibility (tested by luminescence assay) but only PLGA maintained hCEC morphology. The three polymer solutions differed significantly in their viscosity. The lowest viscosity amongst the three polymer solutions was found in PMMA, which produced the largest diameter fibers and higher thickness confirmed using optical light microscope measurements. The PLGA fibers, being the thinnest, were densely packed, so that the hCECs could grow on the surface and maintain their morphology.70

As well as controlling fiber morphology, electrospinning can be used to fabricate specific gross morphology and control the fiber orientation of tissue engineered scaffolds. A study by Kim et al.71 using PCL and collagen type I found the mechanical properties of the radially aligned section of the scaffolds were supported by the randomly orientated sections making the substrate adequate for corneal application. Transparency of the wetted radially aligned scaffolds was comparable to native rabbit cornea between the 400 and 800 nm wavelength range. Cell culture results showed primary rabbit corneal cells (isolated epithelial, endothelial, keratocytes, and limbal stem cells) exhibited significantly higher proliferation rates with significantly higher cell migration rates across the surface of radially aligned fibers compared to randomly orientated fibers. Additionally, they found CECs cultured on radially aligned fibers showed significantly greater expression of ZO-1 and Na⁺/K⁺-ATPase compared to when cultured on randomly orientated fibers.70

Semi-synthetic materials

Gelatin methacrylate. Both, natural and synthetic polymers have their drawbacks, therefore, combinations of biological derived and synthetic materials have attracted attention in the field of tissue engineering. Studies have shown gelatin methacrylate (GelMA) could be useful as a biomaterial with applications in corneal tissue engineering, but evidence of sufficient strength for corneal tissue transplant is not clear as clinically relevant transplant simulations have not been carried out with this material.72 Rizwan et al.19 produced a modification of GelMA to employ it as scaffold for a tissue engineered hCEC monolayer. They developed a sequential hybrid crosslinking process (physical followed by UV crosslinking) to create an improved material, named GelMA+. GelMA+ showed an 8-fold increase in mechanical strength as compared to regular GelMA and slower degradation kinetics in vitro and in vivo. They achieved hydrogel patterning of topographical cues in the range of 1 µm or lower, that improved cell growth and viability. hCEC monolayers grown on GelMA+ scaffolds showed ZO-1 expression, higher cell density and cell size homogeneity compared to GelMA, which are indications of functionally superior monolayers.

Chitosan plus polycaprolactone or PEG. Chitosan is a biomimetic polysaccharide and PCL is a biodegradable polyester and both are biomaterials approved by the Food and Drug Administration (FDA). Wang et al.73 hybridized chitosan and polycaprolactone to create blended membranes. Chitosan has low strength, whereas PCL has good mechanical properties, and the ability to promote cell adhesion and ECM production. The blended membrane was reported to be beneficial in allowing the growth of CECs, and in maintaining their phenotype in vitro. After 14 days of incubation on 25% PCL and 75% chitosan, CECs showed expression of the tight-junction ZO-1, the Na⁺/K⁺-ATPase, and the gap junction protein connexin-43, which were examined to confirm the functional features of the cells. In a more recent study, the same group showed that hCECs cultured on the blended membranes were able to lay down their own ECM matrix containing collagen IV, which is present in DM.74

Chitosan has also been combined with poly(ethylene glycol) (PEG) to form ultrathin hydrogel films.75 The mechanical properties such as tensile strain and ultimate stress were identical to or greater than those of human corneal tissue due to the fine tuning of the PEG content. Transparency of the films was excellent and they were able
to support the attachment and proliferation of sheep CECs. Importantly, they were also subjected to physical manipulation in ex vivo surgical trials on ovine eyes, in which they performed well.

**Emerging technologies**

**Electrosprun/electrosprayed bioactive materials**

Bioactive electrospun materials loaded with drugs to prevent vascularization of the cornea have been investigated. Silk nanofibers loaded with epigallocatechin gallate (EGCG) exhibited a dose-dependent inhibition of human umbilical vein endothelial cell proliferation. Similarly, nanoparticles fabricated by electrospraying to encapsulate biologically active compounds decorated on electrospun membranes are also being investigated for the corneal endothelium. The idea being that the substrate will act two-fold, to deliver cells to the required area while delivering drugs/growth factors to the eye long-term to maintain transplanted cell health. Preliminary studies using polyethylene terephthalate (PET), an FDA approved non-degradable polymer, electrospun from a solution dissolved in 1,1,1,3,3,3-hexafluoroisopropanol, are described here. Fibers were collected on a grounded, static collection plate modified with insulated sections (Figure 10(a) and (b)). The insulating sections were made of cast molded polydimethylsiloxane (PDMS) in a hemispherical shape. The collected fibers formed a transparent membrane on the insulated sections, whereas the fibers collected on the conducting areas formed an opaque frame. Wetting improved the transparency of the membranes (Figure 10(c)). Wetted membranes mounted on a standard contact lens images using optical coherence tomography highlight the close approximation of the membrane on the anterior surface of the lens (Figure 10(d)–(f)). Culturing a human corneal endothelial cell line (HCEC-12) on the surface of the membranes for 1 month indicated the cytompatibility of the membranes, without any requirement for further surface functionalization. Cells did not invade the bulk structure of the membrane, shown in histological sections (Figure 10(g)) and showed a distinct preference for the transparent area of the membranes in comparison to the opaque frames (Figure 10(h)).

**Additive manufacturing**

Since its invention, additive manufacturing, or three-dimensional (3D) printing is being exploited in innovative new ways in applications in engineering, manufacturing, education, art, and medicine. It has caught the attention of tissue engineers due to the possibilities of 3D bioprinting which allows the incorporation of living cells into the printing ink. The process is complex with choice of printing type, materials, cell types, growth, and differentiation factors as well as technical issues with maintaining cell survival and construction formation. Focus on corneal bioprinting has predominantly been on creation of corneal stromal tissues either for transplantation or for use as an in vitro model. A recent study explored the use of 3D-bioprinting to rapidly deposit hCECs onto amniotic membrane to produce a graft for transplantation into a rabbit model of endothelial damage (Figure 11). The cells were deposited onto lyophilized amniotic membrane using extrusion in a gelatin based bioink supplemented with 0.02 % arginylglycylaspartic acid (Arg-Gly-Asp; RGD), a cell adhesion peptide. The structure was designed as 8 mm × 8 mm with a thickness of 0.7 mm and crosslinked with ultraviolet light for 15 s. The hCECs were shown to survive the printing process and attach to the amniotic membrane. The appearance of the hCECs was atypical with no evidence of a confluent, cobblestone
monolayer after 10 days in culture, however, in the rabbit model the graft group did show improvement of corneal clarity after 2 weeks and near complete clarity by 4 weeks. In this study, another biomaterial, amniotic membrane, was required as a base for the printing. When the technology is developed so that the bio-ink produced scaffold alone can be transplanted then this could increase the advantages of this method of graft creation for CECs. The true potential of this application in the field of corneal endothelial tissue engineering is still unknown as there are still many parameters to be optimized.

Conclusion

A huge amount of progress has been made towards development of a tissue engineered corneal endothelial graft. Bioengineering a scaffold material offers some advantages over biologically derived materials as variability can be controlled, materials can be tuned based on their desirable properties to further increase the reproducibility and enable mass production when necessary with batch-batch consistency. A number of different cell biomaterials have been studied for the purpose of endothelial layer construction, but success is limited by the specific requirements of a scaffold material in this context. These include; cytocompatibility, reproducibility, ease of production/supply, transparency, ability to be handled easily by surgeons i.e. flexibility ideally with tunable properties such as thickness. Many of the publications involving scaffold based engineered grafts have only progressed as far as in vitro or in vivo studies and first-in-human studies are very limited. A big challenge is to acquire suitable funding to progress the potential novel tissue engineered grafts along the translational pathway to clinical trial. Even if a particular material is successful in vitro or in vivo, adjusting the manufacturing protocol to comply with good manufacturing practice (GMP) standards and to allow scale up can be challenging. Throughout the development process researchers should be in contact with the relevant regulatory bodies to ensure the correct safety and efficacy studies have been carried out to allow the product to progress towards the treatment of patients.

Acknowledgements

The authors thank Mrs. Jaini Parekh for illustrations of Figures 1, 2, 3, 5, 6, 7, and 11.

Author's contributions

(a) Made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data – MP, VR, KH, VT, RW, SF, SA, HL
(b) Drafted the article or revised it critically for important intellectual content – MP, VR, KH, VT, RW, SF, AH, CW, DP, VJ, NS, JD, SBK, SA, HJL
(c) Approved the version to be published - MP, VR, KH, VT, RW, SF, AH, CW, DP, VJ, NS, JD, SBK, SA, HJL
(d) Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content - MP, VR, KH, VT, RW, SF, AH, CW, DP, VJ, NS, JD, SBK, SA, HJL.

**Declaration of conflicting interests**
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**
The author(s) received no financial support for the research, authorship, and/or publication of this article.

**ORCID iD**

Mohit Parekh https://orcid.org/0000-0002-5186-068X

**References**

1. Zavala J, Jaime GL, Barrientos CR, et al. Corneal endothelium: developmental strategies for regeneration. Eye 2013; 27: 579–588.
2. Navaratnam J, Utheim TP, Rajasekhar VK, et al. Substrates for expansion of corneal endothelial cells towards bioengineering of human corneal endothelium. J Funct Biomater 2015; 6: 917–945.
3. Nishida T. Neurotrophic mediators and corneal wound healing. Ocul Surf 2005; 3: 194–202.
4. Van Horn DL, Sendele DD, Seideman S, et al. Regenerative capacity of the corneal endothelium in rabbit and cat. Invest Ophthalmol Vis Sci 1977; 16: 597–613.
5. Joyce NC. Proliferative capacity of the corneal endothelium. Prog Retin Eye Res 2002; 22: 359–389.
6. Edelhauser HF. The balance between corneal transparency and edema: the Proctor Lecture. Invest Ophthalmol Vis Sci 2006; 47: 1754–1767.
7. Engelmann K, Bednarz J and Böhneke M. Endothelial cell transplantation and growth behavior of the human corneal endothelium. Ophthalmologe 1999; 96: 555–562.
8. Bourne WM. Biology of the corneal endothelium in health and disease. Eye 2003; 17: 912–918.
9. Gain P, Jullienne R, He Z, et al. Global survey of corneal transplantation and eye banking. JAMA Ophthalmol 2013; 134: 167–173.
10. Weiss JS, Moller HU, Aldave AJ, et al. IC3D classification of corneal dystrophies – edition 2. Cornea 2015; 34: 117–159.
11. Nanda GG and Alone DP. Current understanding of the pathogenesis of Fuchs’ endothelial corneal dystrophy. Mol Vis 2019; 25: 295–310.
12. Zarouchlioti C, Sanchez-Pintado B, Hafford Tear NJ, et al. Antisense therapy for a common corneal dystrophy ameliorates TCF4 repeat expansion-mediated toxicity. Am J Hum Genet 2018; 102(4): 528–539.
13. Trindade BLC and Eliazar GC. Descemet membrane endothelial keratoplasty (DMEK): an update on safety, efficacy and patient selection. Clin Ophthalmol 2019; 13: 1549–1557.
14. Stuart AJ, Romano V, Virgili G, et al. Descemet’s membrane endothelial keratoplasty (DMEK) versus Descemet’s stripping automated endothelial keratoplasty (DSEK) for corneal endothelial failure. Cochrane Database Syst Rev 2018; 6(6): CD012097.
15. Parekh M, Leon P, Ruzza A, et al. Graft detachment and rebubbling rate in Descemet membrane endothelial keratoplasty. Surv Ophthalmol 2018; 63(2): 245–250.
16. Ghezzi CE, Rajak-Kovacina J and Kaplan DL. Corneal tissue engineering: recent advances and future perspectives. Tissue Eng Part B Rev 2015; 21(3): 278–287.
17. Jhanji V, Mehta JS, Sharma N, et al. Targeted corneal transplantation. Curr Opin Ophthalmol 2012; 23(4): 324–329.
18. Ong HS, Ang M and Mehta JS. Evolution of therapies for the corneal endothelium: past, present and future approaches. Br J Ophthalmol. Epub ahead of print 24 July 2020. DOI: 10.1136/bjophthalmol-2020-316149.
19. Rizwan M, Peh GSL, Ang HP, et al. Sequentially-crosslinked bioactive hydrogels as nano-patterned substrates with customizable stiffness and degradation for corneal tissue engineering applications. Biomaterials 2017; 120: 139–154.
20. Peh GS, Chng Z, Ang HP, et al. Propagation of human corneal endothelial cells: a novel dual media approach. Cell Transplant 2015; 24(2): 287–304.
21. Mimura T, Yamagami S, Usui T, et al. Necessary prone position time for human corneal endothelial precursor transplantation in a rabbit endothelial deficiency model. Curr Eye Res 2007; 32: 617–623.
22. Okumura N, Sakamoto Y, Fuji K, et al. Rho kinase inhibitor enables cell-based therapy for corneal endothelial dysfunction. Sci Rep 2016; 6: 26113–26113.
23. Okumura N, Koizumi N, Ueno M, et al. ROCK inhibitor converts corneal endothelial cells into a phenotype capable of regenerating in vivo endothelial tissue. Am J Pathol 2012; 181: 268–277.
24. Kinoshita S, Koizumi N, Ueno M, et al. Injection of cultured cells with a ROCK inhibitor for bullous keratopathy. N Engl J Med 2018; 378: 995–1003.
25. Numa K, Imai K, Ueno M, et al. Five-year follow-up of first eleven cases undergoing injection of cultured corneal endothelial cells for corneal endothelial failure. Ophthalmology. Epub ahead of print 5 September 2020. DOI: 10.1016/j.ophtha.2020.09.002.
26. Peh GSL, Ong HS, Adnan K, et al. Functional evaluation of two corneal endothelial cell-based therapies: tissue-engineered construct and cell injection. Sci Rep 2019; 9: 6087.
27. Watanabe S, Oie Y and Fujimoto H. Relationship between corneal guttae and quality of vision in patients with mild fuchs’ endothelial corneal dystrophy. Ophthalmologica 2015; 212: 2103–2109.
28. Parekh M, Ahmad S, Ruzza A, et al. Human corneal endothelial cell cultivation from old donor corneas with forced attachment. Sci Rep 2017; 7: 142.
29. Choi JS, Kim EY, Kim MJ, et al. Factors affecting successful isolation of human corneal endothelial cells for clinical use. Cell Transplant 2014; 23: 845–854.
30. Choi JS, Kim EY, Kim MJ, et al. In vitro evaluation of the interactions between human corneal endothelial cells and extracellular matrix proteins. Biomed Mater 2013; 8: 014108.
31. Yamaguchi M, Ebihara N, Shima N, et al. Adhesion, migration, and proliferation of cultured human corneal...
endothelial cells by laminin-5. Invest Ophthalmol Vis Sci 2011; 52: 679–684.
32. Okumura N, Kakutani K, Numata R, et al. Laminin-511 and -521 enable efficient in vitro expansion of human corneal endothelial cells. Invest Ophthalmol Vis Sci 2015; 56: 2933–2942.
33. Zhao C, Zhou Q, Duan H, et al. Laminin 511 precoating promotes the functional recovery of transplanted corneal endothelial cells. Tissue Eng Part A 2020; 26(21–22): 1158–1168.
34. Parekh M, Ramos T, O’Sullivan F, et al. Human corneal endothelial cells from older donors can be cultured and passaged on cell-derived extracellular matrix. Acta Ophthalmol. Epub ahead of print 10 September 2020. DOI: 10.1111/aos.14614.
35. Tang Z, Akiyama Y and Okano T. Recent development of temperature-responsive cell culture surface using poly (N-isopropylacrylamide). J Polm Sci Part B Polym Phys 2014; 52: 917–926.
36. Ide T, Nishida K, Yamato M, et al. Structural characterization of bioengineered human corneal endothelial cell sheets fabricated on temperature-responsive culture dishes. Biomaterials 2006; 27: 607–614.
37. Lai JY, Chen KH and Hsiue GH. Tissue-engineered human corneal endothelial cell sheet transplantation in a rabbit model using functional biomaterials. Transplantation 2007; 84: 1222–1232.
38. Sumide T, Nishida K, Yamato M, et al. Functional human corneal endothelial cell sheets harvested from temperature-responsive culture surfaces. FASEB J 2006; 20: 392–394.
39. Hsiue GH, Lai JY, Chen KH, et al. A novel strategy for corneal endothelial reconstruction with a bioengineered cell sheet. Transplantation 2006; 81: 473–476.
40. Palchesko RN, Lathrop KL, Funderburgh JL, et al. In vitro expansion of corneal endothelial cells on biomimetic substrates. Sci Rep 2015; 5: 7955.
41. Kudo M, Sonoda Y, Muramatsu R, et al. Immunogenicity of human amniotic membrane in experimental xenotransplantation. IOVS 2001; 42: 1539–1546.
42. Wencan W, Mao Y, Wentao Y, et al. Using basement membrane of human amniotic membrane as a cell carrier for cultivated cat corneal endothelial cell transplantation. Curr Eye Res 2007; 32: 199–215.
43. Ishino Y, Sano Y, Nakamura T, et al. Amniotic membrane as a carrier for cultivated human corneal endothelial cell transplantation. Invest Ophthalmol Vis Sci 2004; 45: 800–806.
44. Amano S. Transplantation of corneal endothelial cells. Nippon Ganka Gakkai Zasshi 2002; 106: 805–835.
45. Utzheim TP, Lyberg T and Rader S. The culture of limbal epithelial cells. Methods Mol Biol 2013; 1014: 103–129.
46. Kobayashi A, Shirao Y, Yoshita T, et al. Temporary amniotic membrane patching for acute chemical burns. Eye (London, England) 2003; 17: 149–158.
47. Meinel L, Hofmann S, Karageorgiou V, et al. The inflammatory responses to silk films in vitro and in vivo. Biomaterials 2005; 26: 147–155.
48. Song JH, Lim SM and Kim J. Characterization of surface modified glycerol/silk fibroin film for application to corneal endothelial cell regeneration. J Biomat Sci Polym Ed 2019; 30: 263–275.
49. Madden PW, Lai JNX, George KA, et al. Human corneal endothelial cell growth on a silk fibroin membrane. Biomaterials 2011; 32: 4076–4084.
50. Vázquez N, Rodríguez-Barrientos CA, Aznar-Cervantes SD, et al. Silk fibroin films for corneal endothelial regeneration: transplant in a rabbit descemet membrane endothelial keratoplasty. Invest Ophthalmol Vis Sci 2017; 58: 3357.
51. Kim DK, Sim BR, Kim JI, et al. Functionalized silk fibroin film scaffold using β-carotene for corneal endothelial cell regeneration. Colloids Surf B Biointerfaces 2018; 164: 340–346.
52. Kim EY, Tripathy N, Cho SA, et al. Bioengineered neo-corneal endothelium using collagen type-I coated silk fibroin film. Colloids Surf B Biointerfaces 2015; 136: 394–401.
53. Kim DK, Sim BR and Khang G. Nature-derived aloe vera gel blended silk fibroin film scaffolds for corneal endothelial cell regeneration and transplantation. ACS Appl Mater Interfaces 2016; 8: 15160–15168.
54. Yoeruek E, Saygili O, Spitzer MS, et al. Human anterior lens capsule as carrier matrix for cultivated human corneal endothelial cells. Cornea 2009; 28: 416–420.
55. Spinnuzzi D, Miron A, Bruinisma M, et al. Evaluation of the suitability of biocompatible carriers as artificial transplants using cultured porcine corneal endothelial cells. Curr Eye Res 2019; 44: 243–249.
56. Bayyoud T, Thaler S, Hofmann J, et al. Decellularized bovine corneal posterior lamellae as carrier matrix for cultivated human corneal endothelial cells. Curr Eye Res 2012; 37: 179–186.
57. Zhang C, Du L, Sun P, et al. Construction of tissue-engineered full-thickness cornea substitute using limbal epithelial cell-like and corneal endothelial cell-like cells derived from human embryonic stem cells. Biomaterials 2017; 124: 180–194.
58. Dong M, Zhao L, Wang F, et al. Rapid porcine corneal decellularization through the use of sodium N-lauroyl glutamate and supernuclease. J Tissue Eng 2019; 10: 2041731419875876.
59. Lin CC, Ritch R, Lin SM, et al. A new fish scale-derived scaffold for corneal regeneration. Eur Cells Mater 2010; 19: 50–57.
60. Van Essen TH, Van Zijl L, Possemiers T, et al. Biocompatibility of a fish scale-derived artificial cornea: cytotoxicity, cellular adhesion and phenotype, and in vivo immunogenicity. Biomaterials 2016; 81: 36–45.
61. Van Essen TH, Lin CC, Lai HJ, et al. A biocornea of fish scales – first results of a research model. Acta Ophthal 2011; 89(s248).
62. Parekh M, Bogerd BVD, Zakaria N, et al. Fish scale-derived scaffolds for culturing human corneal endothelial cells. Stem Cells Int 2018; 2018: 8146834.
63. Levis HJ, Kureshi AK, Massie I, et al. Tissue engineering the cornea: the evolution of RAFT. J Funct Biomater 2015; 6: 50–65.
64. Levis HJ, Peh GS, Toh KP, et al. Plastic compressed collagen as a novel carrier for expanded human corneal endothelial cells for transplantation. PLoS One 2012; 7: e50993.
65. Afewerki S, Sheikhi A, Kannan S, et al. Gelatin-polysaccharide composite scaffolds for 3D cell culture and tissue engineering: towards natural therapeutics. Bioeng Transl Med 2018; 4: 96–115.
66. Kimoto M, Shima N, Yamaguchi M, et al. Development of a bioengineered corneal endothelial cell sheet to fit the corneal curvature. Invest Ophthalmol Vis Sci 2014; 55: 2337–2343.
67. Niu G, Choi JS, Wang Z, et al. Heparin-modified gelatin scaffolds for human corneal endothelial cell transplantation. Biomaterials 2014; 35: 4005–4014.
68. Liang Y, Liu W, Han B, et al. Fabrication and characters of a corneal endothelial cells scaffold based on chitosan. J Mater Sci Mater Med 2011; 22: 175–183.
69. Kennedy S, Lace R, Carserides C, et al. Poly-ε-lysine based hydrogels as synthetic substrates for the expansion of corneal endothelial cells for transplantation. J Mater Sci Mater Med 2019; 30: 102.
70. Kruse M, Walter P, Bauer B, et al. Electro-spun membranes as scaffolds for human corneal endothelial cells. Curr Eye Res 2018; 43: 1–11.
71. Kim JI, Kim JY and Park CH. Fabrication of transparent hemispherical 3D nanofibrous scaffolds with radially aligned patterns via a novel electrospinning method. Sci Rep 2018; 8: 3424.
72. Xiao S, Zhao T, Wang J, et al. Gelatin methacrylate (GelMA)-based hydrogels for cell transplantation: an effective strategy for tissue engineering. Stem Cell Rev Rep 2019; 15: 664–679.
73. Wang TJ, Wang JJ, Hu FR, et al. Applications of biomaterials in corneal endothelial tissue engineering. Cornea 2016; 35: S25–S30.
74. Wang YH, Young TH and Wang TJ. Investigating the effect of chitosan/polyacrylactone blends in differentiation of corneal endothelial cells and extracellular matrix compositions. Exp Eye Res 2019; 185: 107679.
75. Ozcelik B, Brown KD, Blencowe A, et al. Ultrathin chitosan-poly(ethylene glycol) hydrogel films for corneal tissue engineering. Acta Biomater 2013; 9: 6594–6605.
76. Forouzideh N, Nadri S, Fattahi A, et al. Epigallocatechin gallate loaded electrospun silk fibroin scaffold with anti-angiogenic properties for corneal tissue engineering. J Drug Deliv Sci Technol 2020; 56: 101498 (Part A).
77. McCormick R, Pearce I, Kaye SB, et al. Optimisation of a novel bio-substrate as a treatment for atrophic age-related macular degeneration. Front Bioeng Biotechnol 2020; 8: 456.
78. Murphy S and Atala A. 3D bioprinting of tissues and organs. Nat Biotechnol 2015; 32: 773–785.
79. Kim H, Park MN, Kim J, et al. Characterization of cornea-specific bioink: high transparency, improved in vivo safety. J Tissue Eng 2019; 10: 2041731418823382.
80. Ludwig PE, Huff TJ and Zuniga JM. The potential role of bioengineering and three-dimensional printing in curing global corneal blindness. J Tissue Eng 2018; 9: 2041731418769863.
81. Kim KW, Lee SJ, Park SH, et al. Ex vivo functionality of 3D bioprinted corneal endothelium engineered with ribonuclease 5-overexpressing human corneal endothelial cells. Adv Healthc Mater 2018; 7: e1800398.